Stocktoria
Inmune Bio, Inc. INMB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-04
Inmune Bio, Inc. statistics & valuation
Market cap$37.8M
P / B1.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -94766.0% | -304535.7% | -19187.7% | -6938.8% | -16106.6% |
| Net margin | -91866.0% | -300585.7% | -19360.0% | -7299.2% | -16762.4% |
| FCF margin | -47248.0% | — | — | — | — |
| Return on assets | -142.0% | -106.4% | -52.6% | -33.4% | -30.4% |
| Return on equity | -195.3% | -131.1% | -80.4% | -45.4% | -37.8% |
| Debt / equity | — | 0.47× | — | 0.25× | 0.19× |
| Current ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 |
| Revenue growth | 257.1% | -91.0% | -58.6% | 106.6% | 1545.5% |
Source: SEC EDGAR filings · CIK 0001711754 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.